Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery
The University of Texas Health Science Center at San Antonio
80 participants
Nov 1, 2005
INTERVENTIONAL
Conditions
Summary
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism. The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims. 1. To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp. 2. To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals. 3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
Eligibility
Inclusion Criteria4
- age 18-65
- healthy control without diabetes or active organ disease
- Individuals with bariatric surgery
- recurrent hypoglycemia post gastric bypass
Exclusion Criteria4
- pregnancy
- significant anemia
- diabetes currently unless pre-op for bariatric surgery procedure
- GI obstruction
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion
2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01803451